Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the diseases caused by transthyretin (TTR) amyloidosis (ATTR). Co.'s product candidate, AG10, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. Co.'s approach to the treatment of ATTR is designed to mimic a naturally-occurring variant of the TTR gene (T119M) that is considered a rescue mutation because it has been shown to prevent ATTR in individuals carrying pathogenic, or disease-causing, mutations in the TTR gene. We show 12 historical shares outstanding datapoints in our EIDX shares outstanding history coverage, used to compute EIDX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EIDX market cap history over the course of time is important for investors
interested in comparing EIDX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EIDX versus a peer is one thing; comparing
EIDX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EIDX can fluctuate over the course of history.
With this page we aim to empower investors researching EIDX by allowing them to research the EIDX market cap history. |
Free EIDX Email Alerts:
Video: The Importance of Market Cap
